AMLVaran

AMLVaran analyzes targeted next-generation sequencing (NGS) data to detect, filter, annotate, and report somatic variants for clinical interpretation in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).

Key Features:

• Comprehensive Variant Analysis Workflow: Performs end-to-end processing from raw data to final report generation and supports selection among multiple variant calling tools.
• Flexible and Customizable Filtering: Implements a dedicated filtering language (SSDL) for precise and reproducible management of variant lists.
• Annotation and Reporting: Provides extensive variant annotation including curated hotspot regions and driver mutations and generates rule-based clinical diagnostic recommendations.
• Validation Performance: Demonstrated sensitivity of 1.0 and a positive predictive value of 0.96 in validation using 402 AML and MDS samples.
• Coverage Analysis and Reproducibility: Performs comprehensive coverage analysis and supports reproducible variant filtering.
• Adaptability: Adaptable to different targeted panels or whole-exome data and applicable across various tumor entities.

Scientific Applications:

• Clinical diagnostics: Enables detection and reporting of clinically relevant variants in AML and MDS diagnostic workflows.
• Prognostic assessment and therapeutic strategy: Supports patient-specific variant interpretation to inform prognostic evaluation and therapeutic decision-making.
• Oncology research: Facilitates targeted NGS-based studies for variant interpretation, hotspot analysis, and driver mutation characterization.

Methodology:

Raw data processing; selection among multiple variant calling tools; variant filtering using the SSDL language; annotation with curated hotspot regions and driver mutations; comprehensive coverage analysis; reproducible variant filtering; and generation of rule-based clinical reports.